Name: 글로벌 시장 동향
SKU: PH4396
Availability: InStock

보고서 요약(국문)

개요
전 세계 소화불량 치료제 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
소화불량은 식사나 음료 섭취 후 상복부에 불편함이나 통증을 유발하는 소화 장애를 말합니다. 소화불량은 질병 자체가 아니라 위식도 역류 질환(GERD) 및 기타 질환의 증상입니다.
소화불량은 위산 과다 분비, 위염, 소화성 궤양, 위식도 역류 질환(GERD)과 같은 근본적인 원인과 식습관 및 스트레스와 같은 생활 습관 요인 등 다양한 원인으로 인해 발생하는 증상들의 복합적인 결과입니다.
전 세계적인 고령화와 변화하는 식습관 및 생활 방식 트렌드는 소화불량 증상의 증가에 기여하여 시장 성장을 촉진하고 있습니다. 약물 연구, 특히 양성자 펌프 억제제(PPI) 분야의 기술 발전으로 새롭고 매우 효과적인 소화불량 치료법이 개발되었습니다. 또한, 일반의약품(OTC) 소화불량 치료제에 대한 수요가 증가하면서 소비자들은 쉽고 간편하게 치료제를 구할 수 있게 되었습니다.
시장 동향: 동인 및 제약 요인
소화불량 치료에 대한 일반의약품 선호도 증가
일반의약품(OTC) 소화불량 치료제는 처방전 없이 약국과 같은 소매점에서 쉽게 구입할 수 있는 의약품으로, 복부 불편감 및 복부 팽만감과 같은 소화불량 증상을 완화하도록 설계되었습니다. 일반의약품 소화불량 치료제의 인기가 높아짐에 따라 제약 회사들은 관련 제품 개발에 박차를 가하고 있습니다.
양성자 펌프 억제제는 소화불량 치료에 가장 많이 사용되는 약물입니다. 예를 들어, Drug Watch 2023 보고서에 따르면 양성자 펌프 억제제(PPI)는 전 세계에서 가장 흔하게 사용되는 약물 중 하나입니다. 미국에서는 매년 약 1,500만 명이 PPI(프로톤 펌프 억제제)를 사용합니다.
또한, 많은 제약 회사들이 소화불량 치료를 위한 일반의약품(OTC)을 출시하고 있습니다. 예를 들어, 2022년 1월 글렌마크 USA는 워크하르트(Wockhardt)로부터 파모티딘, 세티리진 염산염, 란소프라졸 등 4가지 OTC 의약품에 대한 ANDAS(약식 신약 허가 신청)를 인수했습니다. 이러한 OTC 의약품은 소화불량, 속쓰림, 알레르기, 위산 역류 치료에 사용됩니다.
더 나아가, 소화불량의 증가, 고령화, 위장 건강에 대한 인식 제고, 생활 방식 및 식습관 변화 등이 향후 전 세계 소화불량 치료제 시장 성장을 견인할 주요 요인으로 예상됩니다.
시장 동향: 제약 요인
소화불량 치료제의 부작용은 시장 성장을 저해하는 주요 요인 중 하나입니다. 특히 위산 분비를 줄이는 일부 소화불량 치료제는 두통, 설사, 메스꺼움 등의 부작용을 유발할 수 있습니다.

또한, 대체 치료 옵션의 존재는 시장 성장에 영향을 미칠 수 있습니다. 소화불량 환자들은 약물 치료보다 한약, 식이요법, 생활습관 개선과 같은 대체 치료를 선호할 수 있습니다. 이러한 대체 접근법은 표준 약물 치료에서 환자들을 끌어들일 가능성이 있으며, 이는 예측 기간 동안 시장 성장 잠재력에 영향을 미칠 수 있습니다.
세분화 분석
전 세계 소화불량 치료제 시장은 질병 유형, 약물 유형, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
프로톤 펌프 억제제(PPI) 부문은 시장 점유율의 약 38.2%를 차지했습니다.
제품 유형 부문에서 프로톤 펌프 억제제(PPI)는 38.2%를 차지하며, 예측 기간 동안 시장을 주도할 것으로 예상됩니다. 프로톤 펌프 억제제(PPI)는 기능성 소화불량의 1차 치료제로 간주됩니다. PPI는 기능성 소화불량을 개선하는 데 사용할 수 있는 가장 강력한 위산 억제 약물 중 하나입니다.

또한, NHS Greater Glasgow and Clyde의 2022년 보고서에 따르면, PPI는 1차 진료에서만 연간 약 150만 건의 처방이 발행될 정도로 가장 흔하게 처방되는 약물 계열 중 하나입니다. 이 약물 계열 중 오메프라졸과 란소프라졸은 성인에게 특히 선호되는 선택입니다. 또한, 일반의약품으로 구입할 수 있다는 점은 소화불량 환자들에게 이 약물 계열을 선호하는 이유 중 하나입니다.
오메프라졸과 같은 대표적인 양성자 펌프 억제제(PPI)는 비용 효율성과 폭넓은 접근성으로 환자와 의료 전문가 모두에게 인기를 얻고 있습니다. 오메프라졸은 100캡슐에 약 100.37달러로 저렴하여, 특히 건강 보험 혜택이 충분하지 않은 사람들을 포함하여 많은 사람들이 이용할 수 있습니다. 따라서 이러한 요인들로 인해 해당 시장은 예측 기간 동안 지속적으로 성장할 것으로 예상됩니다.

지리적 분석
북미는 2022년 시장 점유율의 약 37.4%를 차지했습니다.
북미는 제품 승인 증가, 고령 인구 증가, 주요 업체와의 협력 등 여러 요인으로 인해 예측 기간 동안 전체 시장 점유율의 약 37.4%를 유지할 것으로 예상됩니다.
예를 들어, 2023년 3월 Marksans Pharma Ltd는 위산 역류 및 속쓰림 치료에 사용되는 파모티딘 정제의 제네릭 버전에 대해 미국 식품의약국(FDA)의 최종 승인을 받았습니다. 미국 식품의약국(FDA)은 파모티딘 정제 10mg 및 20mg에 대한 일반의약품(OTC) 사용을 위한 약식 신약 신청(ANDA)을 승인했습니다.
또한, 미국의 고령 인구 증가는 시장 성장을 견인하는 주요 요인입니다. 소화불량은 소화액(담즙, 타액, 위액, 소화효소 등) 생성이 감소하는 노년층에서 더 흔하게 나타납니다. 예를 들어, 미국 인구조사국(United States Census Bureau)의 2023년 보고서에 따르면, 미국에서 65세 이상 노년 인구는 약 5,580만 명, 즉 전체 인구의 16.8%에 달하며, 이는 100세 이상 전체 인구 증가율보다 거의 5배 빠른 속도로 증가한 수치입니다. 따라서 나이가 들수록 소화불량 발생 확률이 높아지므로, 이는 예측 기간 동안 해당 지역 시장의 성장을 견인할 것입니다.
COVID-19 영향 분석
소화불량은 스트레스에 민감한 장-뇌 질환이며, COVID-19 팬데믹은 상당한 불안과 스트레스를 유발했기 때문에 COVID-19는 전 세계 소화불량 치료제 시장에 상당한 영향을 미쳤습니다. 본 연구에서는 인구 기반 조사를 통해 COVID-19 팬데믹이 기능성 소화불량의 위장 및 심리적 증상에 미치는 영향을 평가했습니다. 설문조사에 따르면, 코로나19 팬데믹은 기능성 소화불량/과민성 대장 증후군(FD/IBS) 환자에게 부정적인 영향을 미쳤으며, 응답자들은 FD-IBS 중복 증후군을 위장 증상 악화와 관련된 가장 중요한 독립적인 요인으로 꼽았습니다.
또한, 코로나19 감염이 기능성 소화불량(FD) 증상에 미치는 영향을 조사하는 임상 시험이 진행 중입니다. 이 연구의 목표는 코로나19 감염이 기능성 소화불량을 유발하는지 또는 기존 기능성 소화불량 증상을 악화시키는지 확인하는 것입니다. 이 시험은 기능성 소화불량과 코로나19 감염이 있는 환자를 포함하는 전향적 관찰 연구입니다. 연구진은 코로나19에 감염되지 않은 기능성 소화불량 환자 대조군에서 코로나19 감염 전후의 기능성 소화불량 증상 심각도를 평가할 것입니다.

경쟁 환경
소화불량 치료제 시장의 주요 글로벌 업체로는 다케다 제약, 사노피, 헤일레온, 프록터앤갬블, 애보트, 화이자, 우드워드 파마 서비스, 래닛, ANI 파마슈티컬, 살릭스 파마슈티컬 등이 있습니다.
주요 개발 사항
• 2023년 1월, 디지털 약물치료(PDT) 전문 기업인 메타미 헬스는 효과적인 치료법이 부족한 만성 상부 위장관 질환인 기능성 소화불량에 대한 장 지향 최면 요법 프로토콜의 라이선스 계약을 체결했습니다.

• 2022년 7월, 메이지 세이카 파마와 제리아 파마슈티컬은 기능성 소화불량 치료제인 아코피드(아코티아미드)에 대해 태국에서 규제 승인을 받았습니다.

보고서 구매 이유

• 질병 유형, 약물 유형, 투여 경로, 유통 채널 및 지역별 글로벌 소화불량 치료제 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.
• 모든 세그먼트를 포함한 소화불량 치료제 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 포함한 제품 맵핑 자료를 Excel 파일로 제공합니다.

글로벌 소화불량 치료제 시장 보고서는 약 77개의 표, 77개의 그림, 185페이지 분량입니다.
주요 대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Dyspepsia Drugs Market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030 growing at a CAGR of YY% during the forecast period 2023-2030.
Dyspepsia also referred as indigestion that casues discomfort or pain in the upper abdomen, often after eating or drinking. It is not a disease but symptom of gastroesophageal reflux disease (GERD) and other conditions.
Dyspepsia is a combination of symptoms caused by a variety of underlying reasons such as excessive stomach acid production, gastritis, peptic ulcers, gastroesophageal reflux disease (GERD), and lifestyle factors such as dietary intake and stress.
The aging global population, as well as changing food and lifestyle trends, all contribute to an increase in dyspeptic symptoms, propelling market growth. Technological advances in drug research, particularly in the Proton Pump Inhibitor (PPI) category, have resulted in novel and very effective dyspepsia treatments. Furthermore, the shift toward over-the-counter (OTC) dyspepsia medications provides consumers with easy and readily available solutions.
Market Dynamics: Drivers and Restraints
The increasing preference for OTC drugs for dyspepsia treatment
Over-the-counter (OTC) dyspepsia drugs are non-prescription medications that are readily available in retail outlets such as pharmacies and are designed to alleviate symptoms of dyspepsia such as abdominal discomfort and bloating. The growing popularity of over-the-counter dyspepsia medications has pushed pharmaceutical companies.
Proton pump inhibitors are the mostly used drugs to treat dyspepsia. For instance, according to the Drug Watch 2023 article, proton pump inhibitors (PPIs) are among the most commonly used drugs in the world. Almost 15 million people in the U.S. use PPIs every year.
Furthermore, many pharmaceutical companies are launching the OTC drugs for dyspepsia. For instance, in January 2022, Glenmark USA acquired ANDAS for four OTC drugs such as famotidine, cetirizine, hydrochloride, lansoprazole from Wockhardt. These OTC drugs are specifically used to treat indigestion, heartburn, anti-allergy, and acid reflux.
Furthermore, the increasing prevalence of dyspepsia, aging population, growing awareness of gastrointestinal health and changing lifestyles and dietary habits are some of the other major factors that are expected to drive the global dyspepsia drugs market over the forecast period.
Market Dynamics: Restraint
The side effects associated with dyspepsia drugs is one major factor to restrain the market. Some of the dyspepsia drugs, especially those that reduce stomach acid production, may cause headaches, diarrhea and nausea.
Furthermore, the availability of alternative treatment options can affect the market growth. Those individuals with dyspepsia may prefer alternative treatment such as herbal medicines, dietary modifications, or lifestyle changes over pharmaceutical treatments. These alternative approaches have the potential to draw patients away from standard pharmacological treatments, thereby affecting the market's growth potential over the forecast period.
Segment Analysis
The global dyspepsia drugs is segmented based on disease type, drug type, route of administration, mode, distribution channel and region.
The proton pump inhibitor segment accounted for approximately 38.2 % of the market share
The proton pump inhibitors (PPIs) from the product type segment accounted for 38.2% and it is expected to be dominated during the forecast period. The proton pump inhibitors (PPIs) are considered as first line treatment for for functional dyspepsia. PPIs are among the strongest drugs available for gastric suppression that improves functional dyspepsia.
Furthermore, according to NHS Greater Glasgow and Clyde 2022 article, PPIs stands second in most commonly prescribed drug class with almost 1.5 million prescriptions issued yearly by primary care alone. Among these drug class, omeprazole and lansoprazole are higly preferred choice for adults. Also, its availability at OTC makes this drug class a preferred choice for individuals suffering from dyspepsia.
The cost-effectiveness and broad availability of medications like omeprazole, a typical proton pump inhibitor (PPI), increase their popularity among both patients and healthcare practitioners. Omeprazole's modest cost, around $100.37 for 100 capsules, enables accessibility for a wide range of people, particularly those without complete health insurance coverage. Thus, owing to the above factors the segment is expected to dominate over the forecast period.
Geographical Analysis
North America accounted for approximately 37.4% of the market share in 2022
North America is estimated to hold about 37.4% of the total market share throughout the forecast period, owing to the increasing product approvals, rising geriatric population, collaboration with the key players, and others that will drive this region further during the forecast period.
For instance, in March 2023, Marksans Pharma Ltd obtained final approval from the U.S. Food and Drug Administration for its generic version of Famotidine tablets, which are used to treat acid indigestion and heartburn. The US Food and Drug Administration (USFDA) has approved an abbreviated new drug application (ANDA) for Famotidine tablets in strengths of 10 mg and 20 mg for over-the-counter (OTC) usage.
Furthermore, the increasing geriatric population in U.S. is major factor in driving the market forwards. Dyspepsia is more common in elderly people, as it decreases in the production of digestive juices (such as bile, saliva, gastric juice, and enzymes). For instance, according to United States Census Bureau 2023 report, in U.S. older population aging 65 and above has reached about 55.8 million or 16.8%, as it has grown nearly five times faster than the total population over 100 years. Thus, as the age increases the probability of having dyspepsia grows, thereby driving the region market forward over the forecast period.
COVID-19 Impact Analysis
Covid 19 had a substantial impact on the global dyspepsia drugs market, as it is a stress-sensitive gut-brain condition, and the COVID-19 epidemic has caused significant anxiety and stress. A population-based survey was conducted to assess the influence of the COVID-19 pandemic on the gastrointestinal and psychological symptoms of FD. According to the survey, the COVID-19 pandemic had a negative impact on FD/IBS individuals, with respondents indicating FD-IBS overlap syndrome as the most important independent factor linked with worsening gastrointestinal symptoms.
Moreover, a clinical trial is ongoing to look into the effect of COVID-19 infection on the symptoms of functional dyspepsia (FD). The study's goal is to see if COVID-19 infection causes FD or worsens the symptoms of pre-existing FD. The trial is prospective observational research in which patients with FD and COVID-19 infection will be included. The researchers will evaluate the severity of FD symptoms before and after COVID-19 infection in a control group of FD patients who did not develop COVID-19.
Competitive Landscape
The major global players in the dyspepsia drugs market include Takeda Pharmaceutical Company Limited, Sanofi, Haleon plc., Procter & Gamble, Abbott, Pfizer Inc., Woodward Pharma Services LLC, Lannett Company, Inc., ANI Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc and among others.
Key Developments
• In January 2023, metaMe Health, Inc., a prescription digital therapeutics (PDT) company, agreed to licensed gut-directed hypnotherapy protocol for functional dyspepsia, a chronic disorder of the upper gastrointestinal tract that currently lacks substantially effective therapy options.
• In July 2022, Meiji Seika Pharma and Zeria Pharmaceutical granted regulatory approval in Thailand for Acofide (acotiamide) to treat functional dyspepsia.
Why Purchase the Report?
• To visualize the global dyspepsia drugs market segmentation-based on disease type, drug type, route of administration, mode, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of dyspepsia drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global dyspepsia drugs market report would provide approximately 77 tables, 77 figures, and 185 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Drug Type
3.3. Snippet by Route of Administration
3.4. Snippet by Mode
3.5. Snippet by Distribution Channel
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Driver
4.1.1.1. The increasing preference for OTC drugs for dyspepsia treatment
4.1.2. Restraints
4.1.2.1. Side effects associated with the dyspepsia drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Disease Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.1.2. Market Attractiveness Index, By Disease Type
7.2. Functional Dyspepsia*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Organic Dyspepsia
8. By Drug Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.1.2. Market Attractiveness Index, By Drug Type
8.2. Proton Pump Inhibitors*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.2.1. Lansoprazole
8.2.2.2. Omeprazole
8.2.2.3. Esomeprazole
8.3. H-2-receptor Antagonists
8.3.1.1. Cimetidine
8.3.1.2. Famotidine
8.3.1.3. Nizatidine
8.4. Antacids
8.4.1.1. Calcium Carbonate
8.4.1.2. Loperamide
8.4.1.3. Simethicone
8.4.1.4. Sodium Bicarbonate
8.5. Antibiotics
8.5.1.1. Amoxicillin
8.5.1.2. Clarithromycin
8.5.1.3. Metronidazole
8.5.1.4. Tetracycline
8.6. Prokinetics
8.6.1.1. Bethanechol
8.6.1.2. Metoclopramide
8.7. Antidepressants
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Parenteral
10. By Mode
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode
10.1.2. Market Attractiveness Index, By Mode
10.2. Over the Counter*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Prescription
11. By Distribution Channel
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.1.2. Market Attractiveness Index, By Distribution Channel
11.2. Hospital Pharmacies*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Retail Pharmacies
11.4. Online Pharmacies
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode
12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.8.1. U.S.
12.2.8.2. Canada
12.2.8.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode
12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.8.1. Germany
12.3.8.2. UK
12.3.8.3. France
12.3.8.4. Italy
12.3.8.5. Spain
12.3.8.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode
12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.8.1. Brazil
12.4.8.2. Argentina
12.4.8.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode
12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.8.1. China
12.5.8.2. India
12.5.8.3. Japan
12.5.8.4. Australia
12.5.8.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode
12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13. Competitive Landscape
13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis
14. Company Profiles
14.1. Takeda Pharmaceutical Company Limited.
14.1.1. Company Overview
14.1.2. Product Type Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Sanofi
14.3. Haleon plc.
14.4. Procter & Gamble
14.5. Abbott
14.6. Pfizer Inc.
14.7. Woodward Pharma Services LLC
14.8. Lannett Company, Inc.
14.9. ANI Pharmaceuticals, Inc.
14.10. Salix Pharmaceuticals, Inc
LIST NOT EXHAUSTIVE
15. Appendix
15.1. About Us and Services
15.2. Contact Us

언급된 주요 기업들

Takeda Pharmaceutical Company Limited., 4. Key Developments, Sanofi, Haleon plc., Procter & Gamble, Abbott, Pfizer Inc., Woodward Pharma Services LLC, Lannett Company, Inc., ANI Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc

표 목록 (Tables)

List of Tables Table 1 Global Dyspepsia Drug Market Value, By Disease Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Dyspepsia Drug Market Value, By Drug Type, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Dyspepsia Drug Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Dyspepsia Drug Market Value, By Mode, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Dyspepsia Drug Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Dyspepsia Drug Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 7 Global Dyspepsia Drug Market Value, By Disease Type, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Dyspepsia Drug Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 9 Global Dyspepsia Drug Market Value, By Drug Type, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Dyspepsia Drug Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 11 Global Dyspepsia Drug Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Dyspepsia Drug Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 13 Global Dyspepsia Drug Market Value, By Mode, 2022, 2026 & 2030 (US$ Million)

Table 14 Global Dyspepsia Drug Market Value, By Mode, 2021-2030 (US$ Million)

Table 15 Global Dyspepsia Drug Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 16 Global Dyspepsia Drug Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 17 Global Dyspepsia Drug Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 18 Global Dyspepsia Drug Market Value, By Region, 2021-2030 (US$ Million)

Table 19 North America Dyspepsia Drug Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 20 North America Dyspepsia Drug Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 21 North America Dyspepsia Drug Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 22 North America Dyspepsia Drug Market Value, By Mode, 2021-2030 (US$ Million)

Table 23 North America Dyspepsia Drug Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 24 North America Dyspepsia Drug Market Value, By Country, 2021-2030 (US$ Million)

Table 25 South America Dyspepsia Drug Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 26 South America Dyspepsia Drug Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 27 South America Dyspepsia Drug Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 28 South America Dyspepsia Drug Market Value, By Mode, 2021-2030 (US$ Million)

Table 29 South America Dyspepsia Drug Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 30 South America Dyspepsia Drug Market Value, By Country, 2021-2030 (US$ Million)

Table 31 Europe Dyspepsia Drug Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 32 Europe Dyspepsia Drug Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 33 Europe Dyspepsia Drug Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 34 Europe Dyspepsia Drug Market Value, By Mode, 2021-2030 (US$ Million)

Table 35 Europe Dyspepsia Drug Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 36 Europe Dyspepsia Drug Market Value, By Country, 2021-2030 (US$ Million)

Table 37 Asia-Pacific Dyspepsia Drug Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 38 Asia-Pacific Dyspepsia Drug Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 39 Asia-Pacific Dyspepsia Drug Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 40 Asia-Pacific Dyspepsia Drug Market Value, By Mode, 2021-2030 (US$ Million)

Table 41 Asia-Pacific Dyspepsia Drug Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 42 Asia-Pacific Dyspepsia Drug Market Value, By Country, 2021-2030 (US$ Million)

Table 43 Middle East & Africa Dyspepsia Drug Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 44 Middle East & Africa Dyspepsia Drug Market Value, By Drug Type, 2021-2030 (US$ Million)

Table 45 Middle East & Africa Dyspepsia Drug Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 46 Middle East & Africa Dyspepsia Drug Market Value, By Mode, 2021-2030 (US$ Million)

Table 47 Middle East & Africa Dyspepsia Drug Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 48 Takeda Pharmaceutical Company Limited.: Overview

Table 49 Takeda Pharmaceutical Company Limited.: Product Portfolio

Table 50 Takeda Pharmaceutical Company Limited.: Key Developments

Table 51 Sanofi: Overview

Table 52 Sanofi: Product Portfolio

Table 53 Sanofi: Key Developments

Table 54 Haleon plc.: Overview

Table 55 Haleon plc.: Product Portfolio

Table 56 Haleon plc.: Key Developments

Table 57 Procter & Gamble: Overview

Table 58 Procter & Gamble: Product Portfolio

Table 59 Procter & Gamble: Key Developments

Table 60 Abbott: Overview

Table 61 Abbott: Product Portfolio

Table 62 Abbott: Key Developments

Table 63 Pfizer Inc.: Overview

Table 64 Pfizer Inc.: Product Portfolio

Table 65 Pfizer Inc.: Key Developments

Table 66 Woodward Pharma Services LLC: Overview

Table 67 Woodward Pharma Services LLC: Product Portfolio

Table 68 Woodward Pharma Services LLC: Key Developments

Table 69 Lannett Company, Inc.: Overview

Table 70 Lannett Company, Inc.: Product Portfolio

Table 71 Lannett Company, Inc.: Key Developments

Table 72 ANI Pharmaceuticals, Inc.: Overview

Table 73 ANI Pharmaceuticals, Inc.: Product Portfolio

Table 74 ANI Pharmaceuticals, Inc.: Key Developments

Table 75 Salix Pharmaceuticals, Inc.: Overview

Table 76 Salix Pharmaceuticals, Inc.: Product Portfolio

Table 77 Salix Pharmaceuticals, Inc.: Key Developments

그림 목록 (Figures)

List of Figures Figure 1 Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 2 Global Dyspepsia Drug Market Share, By Disease Type, 2022 & 2030 (%)

Figure 3 Global Dyspepsia Drug Market Share, By Drug Type, 2022 & 2030 (%)

Figure 4 Global Dyspepsia Drug Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 5 Global Dyspepsia Drug Market Share, By Mode, 2022 & 2030 (%)

Figure 6 Global Dyspepsia Drug Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 7 Global Dyspepsia Drug Market Share, By Region, 2022 & 2030 (%)

Figure 8 Global Dyspepsia Drug Market Y-o-Y Growth, By Disease Type, 2022-2030 (%)

Figure 9 Functional Dyspepsia Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 10 Organic Dyspepsia Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 11 Global Dyspepsia Drug Market Y-o-Y Growth, By Drug Type, 2022-2030 (%)

Figure 12 Proton Pump Inhibitors Drug Type in Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 13 H-2-receptor Antagonists Drug Type in Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 14 Antacids Drug Type in Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 15 Antibiotics Drug Type in Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 16 Prokinetics Drug Type in Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 17 Antidepressants Drug Type in Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 18 Global Dyspepsia Drug Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 19 Oral Route of Administration in Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 20 Parenteral Route of Administration in Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 21 Global Dyspepsia Drug Market Y-o-Y Growth, By Mode, 2022-2030 (%)

Figure 22 Over the Counter Mode in Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 23 Prescription Mode in Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 24 Global Dyspepsia Drug Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 25 Hospital Pharmacies Distribution Channel in Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 26 Retail Pharmacies Distribution Channel in Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 27 Online Pharmacies Distribution Channel in Global Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 28 Global Dyspepsia Drug Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 29 North America Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 30 Asia-Pacific Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 31 Europe Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 32 South America Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 33 Middle East and Africa Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 34 North America Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 35 North America Dyspepsia Drug Market Share, By Disease Type, 2022 & 2030 (%)

Figure 36 North America Dyspepsia Drug Market Share, By Drug Type, 2022 & 2030 (%)

Figure 37 North America Dyspepsia Drug Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 38 North America Dyspepsia Drug Market Share, By Mode, 2022 & 2030 (%)

Figure 39 North America Dyspepsia Drug Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 40 North America Dyspepsia Drug Market Share, By Country, 2022 & 2030 (%)

Figure 41 South America Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 42 South America Dyspepsia Drug Market Share, By Disease Type, 2022 & 2030 (%)

Figure 43 South America Dyspepsia Drug Market Share, By Drug Type, 2022 & 2030 (%)

Figure 44 South America Dyspepsia Drug Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 45 South America Dyspepsia Drug Market Share, By Mode, 2022 & 2030 (%)

Figure 46 South America Dyspepsia Drug Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 47 South America Dyspepsia Drug Market Share, By Country, 2022 & 2030 (%)

Figure 48 Europe Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 49 Europe Dyspepsia Drug Market Share, By Disease Type, 2022 & 2030 (%)

Figure 50 Europe Dyspepsia Drug Market Share, By Drug Type, 2022 & 2030 (%)

Figure 51 Europe Dyspepsia Drug Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 52 Europe Dyspepsia Drug Market Share, By Mode, 2022 & 2030 (%)

Figure 53 Europe Dyspepsia Drug Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 54 Europe Dyspepsia Drug Market Share, By Country, 2022 & 2030 (%)

Figure 55 Asia-Pacific Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 56 Asia-Pacific Dyspepsia Drug Market Share, By Disease Type, 2022 & 2030 (%)

Figure 57 Asia-Pacific Dyspepsia Drug Market Share, By Drug Type, 2022 & 2030 (%)

Figure 58 Asia-Pacific Dyspepsia Drug Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 59 Asia-Pacific Dyspepsia Drug Market Share, By Mode, 2022 & 2030 (%)

Figure 60 Asia-Pacific Dyspepsia Drug Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 61 Asia-Pacific Dyspepsia Drug Market Share, By Country, 2022 & 2030 (%)

Figure 62 Middle East & Africa Dyspepsia Drug Market Value, 2021-2030 (US$ Million)

Figure 63 Middle East & Africa Dyspepsia Drug Market Share, By Disease Type, 2022 & 2030 (%)

Figure 64 Middle East & Africa Dyspepsia Drug Market Share, By Drug Type, 2022 & 2030 (%)

Figure 65 Middle East & Africa Dyspepsia Drug Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 66 Middle East & Africa Dyspepsia Drug Market Share, By Mode, 2022 & 2030 (%)

Figure 67 Middle East & Africa Dyspepsia Drug Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 68 Takeda Pharmaceutical Company Limited.: Financials

Figure 69 Sanofi: Financials

Figure 70 Haleon plc.: Financials

Figure 71 Procter & Gamble: Financials

Figure 72 Abbott: Financials

Figure 73 Pfizer Inc.: Financials

Figure 74 Woodward Pharma Services LLC: Financials

Figure 75 Lannett Company, Inc.: Financials

Figure 76 ANI Pharmaceuticals, Inc.: Financials

Figure 77 Salix Pharmaceuticals, Inc.: Financials

세계 소화불량 치료제 시장 – 2023-2030

Global Dyspepsia Drugs Market -2023-2030